Junxian Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Junxian Zhao has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Zhongsong Zhang
The Second Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital, Chengdu, China
9 shared publications - Junhao Chen
Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China
8 shared publications - Jingfeng Zhou
School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan Province, 610550, People’s Republic of China
5 shared publications Bing Wang
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
4 shared publicationsJieming Zuo
Department of Urology, the Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People’s Republic of China
4 shared publications- Keyi Gou
Department of Gastrointestinal Surgery, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
4 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Springer Nature in Advanced Composites and Hybrid Materials
- Vol. 9 (5) , 399
Correction: nano-engineered precision strategies for hematological malignancies: current advances and translational roadmap
- 17 September 2026
- Published by Springer Nature in Advanced Composites and Hybrid Materials
- Vol. 9 (5) , 399
Open AccessCorrection: nano-engineered precision strategies for hematological malignancies: current advances and translational roadmap
- Open Access
- 23 August 2026
- Published by Springer Nature in Cancer Nanotechnology
- Vol. 17 (1)
Multimodal nanomedicine for precision colorectal cancer management: integrated diagnosis, targeted therapy, and personalized theranostics
- 23 August 2026
- Published by Springer Nature in Cancer Nanotechnology
- Vol. 17 (1)
Open AccessMultimodal nanomedicine for precision colorectal cancer management: integrated diagnosis, targeted therapy, and personalized theranostics
- Open Access
- 1 August 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-37
Engineering Multimodal Nanomaterials for Prostate Cancer Theranostics: Design Principles, Recent Advances, and Translational Challenges
Prostate cancer (PCa) remains a major clinical challenge because of limitations in early detection, tumor heterogeneity, therapeutic resistance, and metastatic progression. Nanomaterials provide versatile platforms for PCa theranostics by integrating molecular imaging, biomarker detection, targeted delivery, multimodal therapy, and therapeutic response assessment. This review summarizes recent advances in major nanomaterial platforms for PCa theranostics, including lipid-based nanomaterials, polymeric nanoparticles, gold nanoparticles (AuNPs), magnetic nanoparticles (MNPs), biomimetic nanoplatforms, and emerging smart nanocarriers, with emphasis on imaging enhancement, biosensing and liquid biopsy, targeted drug and nucleic acid delivery, phototherapy, sonodynamic and chemodynamic therapy (CDT), immunotherapy, and multimodal combination strategies. These advances reflect a shift from conventional single-function nanocarriers toward engineered multimodal theranostic systems that integrate molecular targeting, stimulus-responsive release, image-guided intervention, combination therapy, and therapeutic response monitoring. Unlike previous reviews that mainly describe nanomaterial categories or isolated applications, this review adopts an engineering-oriented design–function–application–translation framework to clarify how material properties, targeting strategies, and stimulus-responsive designs influence diagnostic performance, therapeutic selectivity, and clinical feasibility. Particular emphasis is placed on prostate-specific membrane antigen (PSMA)-targeted nanoplatforms as representative systems for theranostic integration. Current evidence suggests that nanoplatforms can improve tumor-selective accumulation, imaging sensitivity, biomarker detection, cargo stability, and intracellular delivery while reducing off-target toxicity. However, clinical translation remains limited by heterogeneous biodistribution, protein corona effects, nonspecific uptake, insufficient long-term biosafety data, manufacturing complexity, and batch-to-batch variability. Overall, nanomedicine may support more precise, minimally invasive, and integrated PCa management, but successful translation will require standardized characterization, scalable manufacturing, rigorous safety evaluation, clinically relevant validation, and rational integration with established diagnostic and therapeutic pathways.
- 1 August 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-37
Open AccessEngineering Multimodal Nanomaterials for Prostate Cancer Theranostics: Design Principles, Recent Advances, and Translational Challenges
Prostate cancer (PCa) remains a major clinical challenge because of limitations in early detection, tumor heterogeneity, therapeutic resistance, and metastatic progression. Nanomaterials provide versatile platforms for PCa theranostics by integrating molecular imaging, biomarker detection, targeted delivery, multimodal therapy, and therapeutic response assessment. This review summarizes recent advances in major nanomaterial platforms for PCa theranostics, including lipid-based nanomaterials, polymeric nanoparticles, gold nanoparticles (AuNPs), magnetic nanoparticles (MNPs), biomimetic nanoplatforms, and emerging smart nanocarriers, with emphasis on imaging enhancement, biosensing and liquid biopsy, targeted drug and nucleic acid delivery, phototherapy, sonodynamic and chemodynamic therapy (CDT), immunotherapy, and multimodal combination strategies. These advances reflect a shift from conventional single-function nanocarriers toward engineered multimodal theranostic systems that integrate molecular targeting, stimulus-responsive release, image-guided intervention, combination therapy, and therapeutic response monitoring. Unlike previous reviews that mainly describe nanomaterial categories or isolated applications, this review adopts an engineering-oriented design–function–application–translation framework to clarify how material properties, targeting strategies, and stimulus-responsive designs influence diagnostic performance, therapeutic selectivity, and clinical feasibility. Particular emphasis is placed on prostate-specific membrane antigen (PSMA)-targeted nanoplatforms as representative systems for theranostic integration. Current evidence suggests that nanoplatforms can improve tumor-selective accumulation, imaging sensitivity, biomarker detection, cargo stability, and intracellular delivery while reducing off-target toxicity. However, clinical translation remains limited by heterogeneous biodistribution, protein corona effects, nonspecific uptake, insufficient long-term biosafety data, manufacturing complexity, and batch-to-batch variability. Overall, nanomedicine may support more precise, minimally invasive, and integrated PCa management, but successful translation will require standardized characterization, scalable manufacturing, rigorous safety evaluation, clinically relevant validation, and rational integration with established diagnostic and therapeutic pathways.
- Open Access
- 1 June 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-35
The Application of Nanomaterials in Kidney Stone Disease: Emerging Strategies for Early Diagnosis, Targeted Therapy, and Prevention
Kidney stone disease is one of the most common urologic disorders worldwide and imposes a growing clinical and socioeconomic burden because of its rising prevalence, high recurrence rate, and association with chronic kidney injury and systemic metabolic abnormalities. Calcium oxalate (CaOx) stones remain the predominant stone type, and their formation is now recognized as a multistep process involving urinary supersaturation, crystal nucleation and growth, tubular epithelial injury, oxidative stress, inflammation, and crystal retention. Although current management strategies, including dietary modification, pharmacologic prevention, and endourologic interventions, have substantially improved stone clearance, important limitations remain. These include inadequate early detection, suboptimal prevention of recurrence, insufficient targeting of the local renal microenvironment, and procedure-related complications. Recent advances in nanotechnology offer new opportunities to address these unmet needs. Owing to their large specific surface area, tunable physicochemical properties, versatile surface functionalization, and capacity for multimodal integration, nanomaterials have shown considerable promise in metabolic sensing, urinary biomarker detection, targeted drug delivery, modulation of crystal growth, biomimetic renal targeting, and photothermal or photoresponsive lithotripsy. In parallel, the convergence of nanotechnology with artificial intelligence, smart diagnostic devices, and personalized metabolic profiling is reshaping kidney stone management. This shift is moving the field from passive stone removal toward active risk prediction, dynamic monitoring, and precision prevention. In this review, we summarize recent advances in nanomaterial-based strategies for the diagnosis, treatment, and prevention of kidney stones, with particular emphasis on CaOx disease. We also discuss the major translational barriers, including biocompatibility, long-term safety, regulatory complexity, scalable manufacturing, and cost-effectiveness, and outline future directions for clinically integrated, intelligent, and individualized stone care.
- 1 June 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-35
Open AccessThe Application of Nanomaterials in Kidney Stone Disease: Emerging Strategies for Early Diagnosis, Targeted Therapy, and Prevention
Kidney stone disease is one of the most common urologic disorders worldwide and imposes a growing clinical and socioeconomic burden because of its rising prevalence, high recurrence rate, and association with chronic kidney injury and systemic metabolic abnormalities. Calcium oxalate (CaOx) stones remain the predominant stone type, and their formation is now recognized as a multistep process involving urinary supersaturation, crystal nucleation and growth, tubular epithelial injury, oxidative stress, inflammation, and crystal retention. Although current management strategies, including dietary modification, pharmacologic prevention, and endourologic interventions, have substantially improved stone clearance, important limitations remain. These include inadequate early detection, suboptimal prevention of recurrence, insufficient targeting of the local renal microenvironment, and procedure-related complications. Recent advances in nanotechnology offer new opportunities to address these unmet needs. Owing to their large specific surface area, tunable physicochemical properties, versatile surface functionalization, and capacity for multimodal integration, nanomaterials have shown considerable promise in metabolic sensing, urinary biomarker detection, targeted drug delivery, modulation of crystal growth, biomimetic renal targeting, and photothermal or photoresponsive lithotripsy. In parallel, the convergence of nanotechnology with artificial intelligence, smart diagnostic devices, and personalized metabolic profiling is reshaping kidney stone management. This shift is moving the field from passive stone removal toward active risk prediction, dynamic monitoring, and precision prevention. In this review, we summarize recent advances in nanomaterial-based strategies for the diagnosis, treatment, and prevention of kidney stones, with particular emphasis on CaOx disease. We also discuss the major translational barriers, including biocompatibility, long-term safety, regulatory complexity, scalable manufacturing, and cost-effectiveness, and outline future directions for clinically integrated, intelligent, and individualized stone care.
- Open Access
- 18 May 2026
- Published by Springer Nature in Advanced Composites and Hybrid Materials
- Vol. 9 (4)
Nano-engineered precision strategies for hematological malignancies: current advances and translational roadmap
- 18 May 2026
- Published by Springer Nature in Advanced Composites and Hybrid Materials
- Vol. 9 (4)
Open AccessNano-engineered precision strategies for hematological malignancies: current advances and translational roadmap
- Open Access
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-36
Nanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy
Colorectal cancer (CRC) is a common malignancy that remains difficult to control with surgery, chemotherapy, radiotherapy, and targeted therapy. These challenges arise from tumor heterogeneity, therapy resistance, and frequent relapse or metastasis, especially in advanced disease. In addition, precision approaches are limited by interpatient variability, evolving targets, and suboptimal biomarker performance. Nanodynamic therapy (NDT) is a modular, energy-activated strategy (e.g. PDT, SDT, CDT, and EDT). It can be systematically engineered using a “Structure–Energy Conversion–Reaction Dynamics” framework that links nanoplatform architecture to stimulus-transduction efficiency and spatiotemporally controlled cytotoxic reactions. NDT converts externally applied light, ultrasound, or electric fields into localized oxidative or catalytic cytotoxicity, potentially reducing off-target injury. This approach is particularly relevant to CRC because intracavitary or endoluminal energy delivery enables precise spatiotemporal control that is difficult to achieve with systemic targeting alone. However, NDT alone rarely addresses the full complexity of the heterogeneous, immunosuppressive CRC microenvironment. Efficacy is often limited by hypoxia, immunologically “cold” tumors, and suboptimal synchronization of treatment timing and delivery. These constraints motivate rational combinations with immunotherapy and microenvironment-targeted interventions. In this review, we summarize organ-specific design principles for CRC-focused NDT. Guided by the Structure–Energy Conversion–Reaction Dynamics paradigm, we describe how nanostructure design (e.g. composition, morphology, and interfaces) governs energy deposition and conversion. We then explain how these processes shape ROS/catalytic kinetics and diffusion, and how the resulting dynamics can be tuned for CRC-relevant activation routes. We further discuss how programmable, locally activated modules can be integrated into synergistic regimens that couple tumor debulking and immunogenic cell death with durable immune programming. We also highlight localized hydrogel- or depot-based “logistics layers” that maintain high drug concentrations at resection margins or intraperitoneal sites. These platforms enable repeated external triggering and coordinated multiagent release, helping to overcome systemic co-delivery barriers. Finally, we outline translational priorities, including patient stratification and biomarkers, clinically compatible energy delivery, manufacturability, and tumor access constraints. These considerations may guide the development of CRC-ready NDT platforms toward prospective validation.
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-36
Open AccessNanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy
Colorectal cancer (CRC) is a common malignancy that remains difficult to control with surgery, chemotherapy, radiotherapy, and targeted therapy. These challenges arise from tumor heterogeneity, therapy resistance, and frequent relapse or metastasis, especially in advanced disease. In addition, precision approaches are limited by interpatient variability, evolving targets, and suboptimal biomarker performance. Nanodynamic therapy (NDT) is a modular, energy-activated strategy (e.g. PDT, SDT, CDT, and EDT). It can be systematically engineered using a “Structure–Energy Conversion–Reaction Dynamics” framework that links nanoplatform architecture to stimulus-transduction efficiency and spatiotemporally controlled cytotoxic reactions. NDT converts externally applied light, ultrasound, or electric fields into localized oxidative or catalytic cytotoxicity, potentially reducing off-target injury. This approach is particularly relevant to CRC because intracavitary or endoluminal energy delivery enables precise spatiotemporal control that is difficult to achieve with systemic targeting alone. However, NDT alone rarely addresses the full complexity of the heterogeneous, immunosuppressive CRC microenvironment. Efficacy is often limited by hypoxia, immunologically “cold” tumors, and suboptimal synchronization of treatment timing and delivery. These constraints motivate rational combinations with immunotherapy and microenvironment-targeted interventions. In this review, we summarize organ-specific design principles for CRC-focused NDT. Guided by the Structure–Energy Conversion–Reaction Dynamics paradigm, we describe how nanostructure design (e.g. composition, morphology, and interfaces) governs energy deposition and conversion. We then explain how these processes shape ROS/catalytic kinetics and diffusion, and how the resulting dynamics can be tuned for CRC-relevant activation routes. We further discuss how programmable, locally activated modules can be integrated into synergistic regimens that couple tumor debulking and immunogenic cell death with durable immune programming. We also highlight localized hydrogel- or depot-based “logistics layers” that maintain high drug concentrations at resection margins or intraperitoneal sites. These platforms enable repeated external triggering and coordinated multiagent release, helping to overcome systemic co-delivery barriers. Finally, we outline translational priorities, including patient stratification and biomarkers, clinically compatible energy delivery, manufacturability, and tumor access constraints. These considerations may guide the development of CRC-ready NDT platforms toward prospective validation.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-32
Nanomedicine Targeting Cancer-Associated Fibroblasts in Prostate Cancer: From Biological Mechanisms to Integrated Theranostic Strategies
Prostate cancer (PCa) is the second most common malignancy in men worldwide. Advanced stages are characterized by tumor heterogeneity, metastasis, and resistance to androgen deprivation therapy and chemotherapy. Cancer-associated fibroblasts (CAFs), the predominant stromal cells in the PCa tumor microenvironment (TME), critically drive tumor progression, metastasis, and therapeutic resistance. Nanomedicine represents a transformative strategy for targeting CAFs. It leverages engineered nanomaterials to achieve precise drug delivery, improved bioavailability, and multimodal theranostic capabilities, which integrate diagnosis with therapy. This review comprehensively examines advances in nanomaterial-based strategies for CAF-targeted therapy in PCa. We first delineate the biology of CAFs in PCa, encompassing their origins, activation mechanisms, key markers (e.g, α-SMA and FAP), phenotypic heterogeneity, and intricate crosstalk with cancer cells, immune cells, and the extracellular matrix (ECM). We then evaluate nanomaterial-based targeting strategies and therapeutic modalities, including CAF depletion, reprogramming, and extracellular matrix remodeling, for the treatment of PCa. Subsequently, we discuss CAF-targeted nanoplatforms for theranostics, including molecular imaging probes (e.g., 68Ga-FAPI) and image-guided delivery systems that integrate precise diagnosis with therapy. Finally, we address key challenges, particularly CAF heterogeneity and nanomaterial biosafety, and outline future directions, including gene-editing integration, multi-stimuli-responsive systems, and synergistic immunotherapy combinations. Collectively, this review underscores the transformative potential of integrating CAF biology with nanotechnology to overcome therapeutic resistance in PCa and advance precision oncology.
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-32
Open AccessNanomedicine Targeting Cancer-Associated Fibroblasts in Prostate Cancer: From Biological Mechanisms to Integrated Theranostic Strategies
Prostate cancer (PCa) is the second most common malignancy in men worldwide. Advanced stages are characterized by tumor heterogeneity, metastasis, and resistance to androgen deprivation therapy and chemotherapy. Cancer-associated fibroblasts (CAFs), the predominant stromal cells in the PCa tumor microenvironment (TME), critically drive tumor progression, metastasis, and therapeutic resistance. Nanomedicine represents a transformative strategy for targeting CAFs. It leverages engineered nanomaterials to achieve precise drug delivery, improved bioavailability, and multimodal theranostic capabilities, which integrate diagnosis with therapy. This review comprehensively examines advances in nanomaterial-based strategies for CAF-targeted therapy in PCa. We first delineate the biology of CAFs in PCa, encompassing their origins, activation mechanisms, key markers (e.g, α-SMA and FAP), phenotypic heterogeneity, and intricate crosstalk with cancer cells, immune cells, and the extracellular matrix (ECM). We then evaluate nanomaterial-based targeting strategies and therapeutic modalities, including CAF depletion, reprogramming, and extracellular matrix remodeling, for the treatment of PCa. Subsequently, we discuss CAF-targeted nanoplatforms for theranostics, including molecular imaging probes (e.g., 68Ga-FAPI) and image-guided delivery systems that integrate precise diagnosis with therapy. Finally, we address key challenges, particularly CAF heterogeneity and nanomaterial biosafety, and outline future directions, including gene-editing integration, multi-stimuli-responsive systems, and synergistic immunotherapy combinations. Collectively, this review underscores the transformative potential of integrating CAF biology with nanotechnology to overcome therapeutic resistance in PCa and advance precision oncology.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 18079-18113
The Neuroimmune Axis in Atopic Dermatitis: From Pathogenic Mechanisms to Targeted Neuroimmunotherapy
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease in which intense pruritus and eczematous lesions arise from tightly coupled disturbances of the nervous and immune systems. Emerging evidence indicates that a dysregulated neuroimmune axis—as reflected by peripheral neuronal sensitization, epidermal barrier dysfunction, and central itch processing—plays a central role in disease onset, persistence, and clinical heterogeneity. In this review, we synthesize current knowledge on the neuroimmune mechanisms that drive AD, focusing on how cytokines such as IL-31, IL-4/IL-13, TSLP and IL-33, together with neuropeptides including substance P, CGRP and VIP, establish self-reinforcing itch–scratch and inflammation loops at the level of the skin and the central nervous system. We then highlight recent multi-omics and systems biology approaches, including single-cell and spatial transcriptomics, neuroimaging, and microbiome profiling, that have reshaped the understanding of neuroimmune “neighbourhoods” and the gut–skin–brain axis in AD. Building on these mechanistic insights, we summarize key neuroimmune biomarkers—such as NGF, IL-31, TARC/CCL17, S100 proteins, barrier-related lipids, neurofunctional readouts from fMRI, and microbial signatures—and discuss their potential for improving diagnosis, patient stratification, and treatment monitoring within a precision medicine framework. Finally, we review established and emerging neuroimmune-targeted therapies, including IL-4/IL-13 and IL-31 pathway inhibitors, JAK inhibitors, OX40/OX40L-directed biologics, TRP and NK1R antagonists, phototherapy, and microbiome-based interventions, with a particular emphasis on biomarker-guided sequencing and combination strategies. Overall, we propose that positioning the neuroimmune axis at the core of AD pathogenesis provides a conceptual basis for developing stratified, durable, and patient-centred neuroimmunotherapy, while also outlining the remaining challenges regarding clinical validation of biomarkers, long-term safety, accessibility, and implementation across diverse patient populations.
- 1 December 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 18079-18113
Open AccessThe Neuroimmune Axis in Atopic Dermatitis: From Pathogenic Mechanisms to Targeted Neuroimmunotherapy
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease in which intense pruritus and eczematous lesions arise from tightly coupled disturbances of the nervous and immune systems. Emerging evidence indicates that a dysregulated neuroimmune axis—as reflected by peripheral neuronal sensitization, epidermal barrier dysfunction, and central itch processing—plays a central role in disease onset, persistence, and clinical heterogeneity. In this review, we synthesize current knowledge on the neuroimmune mechanisms that drive AD, focusing on how cytokines such as IL-31, IL-4/IL-13, TSLP and IL-33, together with neuropeptides including substance P, CGRP and VIP, establish self-reinforcing itch–scratch and inflammation loops at the level of the skin and the central nervous system. We then highlight recent multi-omics and systems biology approaches, including single-cell and spatial transcriptomics, neuroimaging, and microbiome profiling, that have reshaped the understanding of neuroimmune “neighbourhoods” and the gut–skin–brain axis in AD. Building on these mechanistic insights, we summarize key neuroimmune biomarkers—such as NGF, IL-31, TARC/CCL17, S100 proteins, barrier-related lipids, neurofunctional readouts from fMRI, and microbial signatures—and discuss their potential for improving diagnosis, patient stratification, and treatment monitoring within a precision medicine framework. Finally, we review established and emerging neuroimmune-targeted therapies, including IL-4/IL-13 and IL-31 pathway inhibitors, JAK inhibitors, OX40/OX40L-directed biologics, TRP and NK1R antagonists, phototherapy, and microbiome-based interventions, with a particular emphasis on biomarker-guided sequencing and combination strategies. Overall, we propose that positioning the neuroimmune axis at the core of AD pathogenesis provides a conceptual basis for developing stratified, durable, and patient-centred neuroimmunotherapy, while also outlining the remaining challenges regarding clinical validation of biomarkers, long-term safety, accessibility, and implementation across diverse patient populations.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 15235-15275
Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer
Bladder cancer (BC) is a prevalent urinary malignancy characterized by high recurrence rates and suboptimal long-term outcomes from traditional treatments such as surgery, chemotherapy, and radiotherapy. T-cell-based immunotherapy has emerged as a promising approach, harnessing T cells’ capacity to target and destroy tumor cells, yet it faces challenges from the immunosuppressive tumor microenvironment (TME), immune evasion, and T-cell exhaustion. Nanomaterials offer innovative solutions by enabling targeted delivery of antigens, checkpoint inhibitors, and immunomodulators; remodeling the TME through metabolic interventions (eg, hypoxia alleviation and adenosine reduction); and enhancing T-cell infiltration and persistence with stimulus-responsive systems like pH-sensitive nanoparticles and biomimetic vesicles. This review systematically examines nanomaterial integration to amplify T-cell-mediated immunity in BC, covering T-cell origins, differentiation (eg, CD8+ cytotoxic and CD4+ helper subsets), roles in the TME, and exhaustion mechanisms driven by factors like PD-1 and TOX. We discuss key strategies including direct immune enhancement via immunogenic cell death induction, metabolic reprogramming to optimize T-cell function, and sustained activation for improved persistence. In conclusion, these nanomaterial-enhanced therapies address critical barriers, promoting precise and synergistic immune responses. Future prospects highlight AI-driven designs, personalized medicine, and clinical translation to tackle heterogeneity, biosafety, and resistance for durable BC remission.
- 1 December 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 15235-15275
Open AccessNanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer
Bladder cancer (BC) is a prevalent urinary malignancy characterized by high recurrence rates and suboptimal long-term outcomes from traditional treatments such as surgery, chemotherapy, and radiotherapy. T-cell-based immunotherapy has emerged as a promising approach, harnessing T cells’ capacity to target and destroy tumor cells, yet it faces challenges from the immunosuppressive tumor microenvironment (TME), immune evasion, and T-cell exhaustion. Nanomaterials offer innovative solutions by enabling targeted delivery of antigens, checkpoint inhibitors, and immunomodulators; remodeling the TME through metabolic interventions (eg, hypoxia alleviation and adenosine reduction); and enhancing T-cell infiltration and persistence with stimulus-responsive systems like pH-sensitive nanoparticles and biomimetic vesicles. This review systematically examines nanomaterial integration to amplify T-cell-mediated immunity in BC, covering T-cell origins, differentiation (eg, CD8+ cytotoxic and CD4+ helper subsets), roles in the TME, and exhaustion mechanisms driven by factors like PD-1 and TOX. We discuss key strategies including direct immune enhancement via immunogenic cell death induction, metabolic reprogramming to optimize T-cell function, and sustained activation for improved persistence. In conclusion, these nanomaterial-enhanced therapies address critical barriers, promoting precise and synergistic immune responses. Future prospects highlight AI-driven designs, personalized medicine, and clinical translation to tackle heterogeneity, biosafety, and resistance for durable BC remission.